Evaluating pancreatic cancer changes during treatment
Official title: Pancreatic Cancer Evolution Upon Treatment
Run by IRCCS San Raffaele · NCT05195281 · Data updated 2026-11-12
This study is testing how pancreatic cancer changes during treatment in patients who have early-stage disease by comparing samples taken before and after chemotherapy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 80 (estimated) |
| Sponsor | IRCCS San Raffaele Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Milan) |
| Status | Recruiting |
| Started | July 14, 2021 |
| Main results expected | September 28, 2027 |
| Study ends | December 31, 2027 |
| Registry record updated | January 15, 2026 |
| Trial ID | NCT05195281 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults aged 18 and older with locally advanced pancreatic cancer who have undergone initial EUS-guided tissue acquisition.
✕Probably not a fit
Patients with malignancies other than pancreatic ductal adenocarcinoma or those experiencing disease progression will not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This project evaluates the different subtypes of pancreatic cancer through EUS-guided fine needle biopsy (FNB) sampling. It focuses on patients with non-metastatic pancreatic cancer who have undergone initial diagnostic procedures. The study aims to analyze how pancreatic cancer evolves over time by comparing initial and subsequent biopsy samples for histological diagnosis and tumor macromolecule extraction. This systematic approach could provide insights into the effectiveness of neoadjuvant chemotherapy.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding of pancreatic cancer evolution and more effective treatment strategies.
How similar studies have gone: While similar studies have explored pancreatic cancer treatment responses, this specific approach utilizing EUS-guided FNB for real-time evaluation is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age ≥ 18 years * Willing to sign informed consent * Patient with CT scan or MRI or EUS defining the lesion as locally advanced * Patient who already underwent EUS-TA for solid lesion of the pancreas positive for pancreatic ductal adenocarcinoma (PDAC) * Patient undergoing neoadjuvant chemotherapy * Patient primarily followed at San Raffaele Hospital Exclusion Criteria: * Patients not willing to sign informed consent * Pregnancy and breastfeeding * Cytology positive for malignancies other than PDAC * Patient undergoing progression at re-staging CT scan
Where it's running
-
IRCCS San Raffaele Hospital
Milan, Italy Recruiting
Study contacts
- Study coordinator: Livia Archibugi, MD
- Email: archibugi.livia@hsr.it
- Phone: +39-02-26432471
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
-
Using contrast-enhanced ultrasound to check for local pancreatic cancer recurrence after surgery
This pilot test uses contrast-enhanced ultrasound to see if it can help detect return of pancreatic cancer after surgery in patients being watched with CT scans.
-
Combination of ivermectin with standard skin-protective care for daraxonrasib-related skin toxicity in pancreatic cancer
This study tests whether adding ivermectin to standard preventive skin care helps people with pancreatic cancer who develop skin side effects from daraxonrasib.
-
Becotatug Vedotin Plus Anti-PD-1 and S-1 in EGFR-Positive Advanced Pancreatic Cancer
This study tests a three-drug regimen (becotatug vedotin, an anti-PD-1 therapy, and S-1) in adults with EGFR-positive advanced pancreatic cancer who have not responded to at least one prior therapy.
-
Blood protein biomarkers to help diagnose pancreatic cancer in adults
This study tests whether blood protein biomarkers can help detect pancreatic ductal adenocarcinoma and tell it apart from chronic pancreatitis and mucinous pancreatic lesions, and whether combining markers with CA 19-9 improves accuracy.
-
Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Cancer (Phase 1)
This early-stage study tests whether giving Lm-LLO-TT directly into the belly with low-dose gemcitabine is safe and tolerable for adults with previously treated, unresectable or metastatic pancreatic cancer.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.